A phase I trial of fixed dose rate gemcitabine plus capecitabine in metastatic cancer patients

Annals of Oncology

Volumn 18, Issue 3, 2007, Pages 576-580

  Santini, D ^a   Virzi V ^a   Vincenzi, B ^a   Rocci, L ^a   Leoni, V ^a   Tonini, G ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Capecitabine; Fixed dose rate; Gemcitabine; Phase I study

Indexed keywords

CAPECITABINE; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BLEEDING; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEUKOPENIA; LIVER TOXICITY; MALE; MAXIMUM TOLERATED DOSE; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OPEN STUDY; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT DURATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; FLUOROURACIL; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS; TREATMENT OUTCOME;

EID: 33847633117     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl440     Document Type: Article

References (16)

1. Heinemann V, Xu YZ, Chubb S et al. Inhibition of ribonucleotide reduction in CCRFCEM cells by 2′,2′-difluorodeoxycytidine. Mol Pharmacol 1990; 38: 567-572.
2. Ren Q, Kao V, Grem JL. Cytotoxicity and DNA fragmentation associated with sequential gemcitabine and 5-fluoro-2′-deoxyuridine in HT-29 colon cancer cells. Clin Cancer Res 1998; 4: 2811-2818.
3. Grunewald R, Kantarjian H, Keating MJ et al. Pharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycytidine (gemcitabine) administration in leukemia. Cancer Res 1990; 50: 6823-6826.
4. Abbruzzese JL, Grunewald R, Weeks EA et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991; 9: 491-498.
5. Tempero M, Plunkett W, Ruiz van Haperen V et al. Randomized phase II comparison of dose-intense gemcitabine: Thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 2003; 21: 3402-3408.
6. Poplin E, Levy DE, Berlin J et al. Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion [FDR]) versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201). ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Suppl); 2006: LBA4004.
7. Reigner B, Blesch K, Weidekamm E. Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 2001; 40: 85-104.
8. Burris HA III, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997; 15: 2403-2413.
9. Kindler HL. Front-line therapy of advanced pancreatic cancer. Semin Oncol 2005; 32 (Suppl 9): S33-S36.
10. Rodney A, Dieringer P, Mathew P et al. Phase II study of capecitabine combined with gemcitabine in the treatment of androgen-independent prostate cancer previously treated with taxanes. Cancer 2006; 106: 2143-2147.
11. Cunningham D, Chau I, Stocken D et al. Phase III randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer. Eur J Cancer Suppl 2005; 3: 4 (European Cancer Conference Organization).
12. Rini BI, Weinberg V, Small EJ. A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma. Cancer 2005; 103: 553-558.
13. Schilsky RL, Bertucci D, Vogelzang NJ et al. Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer. J Clin Oncol 2002; 20: 582-587.
14. NCI CTC Toxicity scale Version 2.0. www.eortc.be/Services/Doc/ctc/ CTCvs2.doc (2000).
15. Therasse P. Measuring the clinical response. What does it mean? Eur J Cancer 2002; 18: 17-23.
16. Rini BI, Vogelzang NJ, Dumas MC et al. Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol 2000; 18: 2419-2426.